Advanced Breast Cancer, Breast Neoplasm Female, Surgery
Conditions
Keywords
Breast Neoplasm Female, Locoregional surgery, In de novo stage IV brest cancer, Overall survival, Locoregional progression free survival, Distant progression free survival
Brief summary
Current guidelines lack definitive evidences about the relative benefits of locoregional surgery for the primary tumor in de novo stage IV breast cancer. The aim of this study (SYSBTC-001) was to investigate the role of locoregional surgery for primary tumor in de novo stage IV breast cancer.
Interventions
PROCEDURELocoregional surgery
Patients had pathologically confirmed operable stage IV breast infiltrating carcinoma at initial presentation, and had locoregional surgery for the breast cancer.
Sponsors
Sun Yat-sen University
First People's Hospital of Foshan
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Operable stage IV breast cancer patients,whose primary lesion is invasive breast cancer confirmed by pathology, and metastases can be confirmed by pathology or imageology examination. * ECOG-PS 0-2. * Bone marrow, liver and kidney should be fully functional. * Patients received the locoregional surgery of the primary tumor in de novo in our center, or didn't received the locoregional surgery of the primary tumor in de novo. * For the patient who accepted systematic treatment before operation, the systematic treatment must be administered within a year since diagnosed.
Exclusion criteria
* Accompanied with other primary malignant tumors. * Patients who can't plan for follow-up effectively and regularly. * Multiple liver metastasis and ALT/AST four times higher than normal at patients' first diagnosis.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | 5 years | The association between locoregional surgery and overall survival (OS), which defined as the time from the beginning of diagnosis of breast cancer to the death with any causes. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Locoregional progression free survival | 5 years | Defined as time between the time of diagnosis and the time of locoregional recurrence, or death occurred. |
| Distant progression free survival | 5 years | Distant disease free survival (D-DFS), which defined as the time from the diagnosis of de novo stage IV breast cancer to the confirmed time of distant progression, or death due to any other cause. |
Countries
China
Contacts
Primary ContactHerui Yao, PhD
Backup ContactYunfang Yu, MD
Outcome results
None listed